The Full Wiki

More info on Blonanserin

Blonanserin: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
CAS number 132810-10-7
ATC code none
PubChem 125564
ChemSpider 111697
Chemical data
Formula C23H30FN3 
Mol. mass 367.50 g/mol
SMILES eMolecules & PubChem
Therapeutic considerations
Pregnancy cat.  ?
Legal status Prescription only
Routes Oral

Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia.[1][2][3] Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms and excessive sedation and hypotension.[3]

Blonanserin acts as a mixed 5-HT2 (Ki = 3.98 nM) and D2 receptor (Ki = 14.8 nM) antagonist.[4] It also exerts some blockade of α1-adrenergic receptors (Ki = 56.3 nM) and has low affinity for the sigma receptor (IC50 = 286 nM).[4] Blonanserin lacks significant affinity for numerous other sites including 5-HT1, 5-HT3, D1, α2-adrenergic, β-adrenergic, H1, mACh, and the monoamine transporters.[4]

See also


  1. ^ Deeks ED, Keating GM (January 2010). "Blonanserin: a review of its use in the management of schizophrenia". CNS Drugs 24 (1): 65–84. doi:10.2165/11202620-000000000-00000. PMID 20030420. 
  2. ^ Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y (2009). "The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study". CNS Drugs 23 (7): 615–25. PMID 19552488. 
  3. ^ a b Heading CE (November 1998). "AD-5423 (Dainippon Pharmaceutical Co Ltd)". IDrugs : the Investigational Drugs Journal 1 (7): 813–7. PMID 18465651. 
  4. ^ a b c Oka M, Noda Y, Ochi Y, et al. (January 1993). "Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties". The Journal of Pharmacology and Experimental Therapeutics 264 (1): 158–65. PMID 8093723. 


Got something to say? Make a comment.
Your name
Your email address